Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Frey

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|November 22, 2011
Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approachLeonid Gibiansky, Nicolas Frey
Journal of Clinical Pharmacology|March 19, 2013
Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid ArthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Clinical Pharmacology|February 26, 2013
Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Clinical Pharmacology|January 26, 2010
Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritisNicolas Frey, Susan Grange, Thasia Woodworth
Journal of Clinical Pharmacology|December 17, 2011
Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin modelPetra M Jauslin, Mats O Karlsson, Nicolas Frey
Pharmaceutical Research|July 12, 2017
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease PatientsSimon Buatois, Sylvie Retout, Nicolas Frey, et al.
Journal of Clinical Pharmacology|November 27, 2009
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteersHanna E Silber, Nicolas Frey, Mats O Karlsson
Journal of Clinical Pharmacology|March 12, 2010
Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetesPetra M Jauslin, Nicolas Frey, Mats O Karlsson
Pharmaceutical Research|June 8, 2013
Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokineticsFrançois Pierre Combes, Sylvie Retout, Nicolas Frey, et al.
Pharmaceutical Statistics|April 4, 2019
From waterfall plots to spaghetti plots in early oncology clinical developmentFrancois Mercier, Nicola Consalvo, Nicolas Frey, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Journal of Pharmacokinetics and Pharmacodynamics|November 22, 2011
Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approachLeonid Gibiansky, Nicolas Frey
Journal of Clinical Pharmacology|March 19, 2013
Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid ArthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Clinical Pharmacology|February 26, 2013
Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Clinical Pharmacology|January 26, 2010
Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritisNicolas Frey, Susan Grange, Thasia Woodworth
Journal of Clinical Pharmacology|December 17, 2011
Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin modelPetra M Jauslin, Mats O Karlsson, Nicolas Frey
Pharmaceutical Research|July 12, 2017
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease PatientsSimon Buatois, Sylvie Retout, Nicolas Frey, et al.
Journal of Clinical Pharmacology|November 27, 2009
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteersHanna E Silber, Nicolas Frey, Mats O Karlsson
Journal of Clinical Pharmacology|March 12, 2010
Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetesPetra M Jauslin, Nicolas Frey, Mats O Karlsson
Pharmaceutical Research|June 8, 2013
Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokineticsFrançois Pierre Combes, Sylvie Retout, Nicolas Frey, et al.
Pharmaceutical Statistics|April 4, 2019
From waterfall plots to spaghetti plots in early oncology clinical developmentFrancois Mercier, Nicola Consalvo, Nicolas Frey, et al.
Pageof 6